Period:
Draw Mode:
| Volume | 3,566,163 |
|
|||||
| News | - | ||||||
| Day High | 16.11 | Low High |
|||||
| Day Low | 15.755 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ImmunoGen Inc | IMGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.13 | -0.81% | 15.87 | 16:16:03 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 16.03 | 15.755 | 16.11 | 15.87 | 16.00 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 31,571 | 3,566,163 | $ 15.93 | $ 56,812,578 | - | 3.605 - 20.69 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:31:46 | priorref | 9,683 | $ 15.87 | USD |
ImmunoGen (IMGN) Options Flow Summary
ImmunoGen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.95B | 248.94M | - | 108.78M | -222.93M | -0.90 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ImmunoGen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.97 | 16.11 | 14.47 | 15.19 | 2,898,228 | 0.90 | 6.01% |
| 1 Month | 16.04 | 16.435 | 14.41 | 15.47 | 3,374,457 | -0.17 | -1.06% |
| 3 Months | 18.64 | 20.69 | 13.83 | 16.47 | 4,175,673 | -2.77 | -14.86% |
| 6 Months | 3.71 | 20.69 | 3.66 | 14.12 | 6,061,464 | 12.16 | 327.76% |
| 1 Year | 4.68 | 20.69 | 3.605 | 10.64 | 4,806,316 | 11.19 | 239.1% |
| 3 Years | 3.53 | 20.69 | 3.095 | 8.06 | 3,481,966 | 12.34 | 349.58% |
| 5 Years | 9.50 | 20.69 | 1.65 | 6.69 | 3,132,668 | 6.37 | 67.05% |
ImmunoGen Description
| Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have licensed limited rights to use the ADC technology in their therapies. |